Clinical Trials on IDH1 R132G

Total 81 results

Rigel Pharmaceuticals
Nationwide Children's Hospital

Not yet recruiting

Study of Olutasidenib and Temozolomide in HGG

Astrocytoma | High Grade Glioma | Oligodendroglioma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | Spinal Tumor | Astrocytoma, Grade III | Astrocytoma, Grade IV | IDH1 Mutation | WHO Grade IV Glioma | Thalamus Tumor | IDH1 R132 | IDH1 R132C | IDH1 R132H and other conditions

United States, Australia, United Kingdom, Canada, Germany, Netherlands
University of Chicago

Recruiting

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

Myeloproliferative Neoplasm | Blood Cancer | IDH2 Gene Mutation | IDH1 Mutation | IDH Mutation

United States
Istituto Clinico Humanitas
Celgene

Unknown

Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia (Euro_IDH_AML)

Acute Myeloid Leukemia | IDH2 Gene Mutation | IDH1 Gene Mutation

Italy
Assistance Publique - Hôpitaux de Paris

Unknown

Non Invasive Detection of IDH1/2 Mutation in Gliomas (IDASPE)

Glioma | IDH1/IDH2 Mutation

France
Massachusetts General Hospital
Agios Pharmaceuticals, Inc.

Completed

IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

IDH1 Mutation Myeloid Neoplasms

United States
AnHeart Therapeutics Inc.

Recruiting

IDH1 Inhibitor AB-218 in Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumor

Cholangiocarcinoma With IDH1 Mutation | Solid Tumors With IDH1 Mutation

China
Massachusetts General Hospital
GlaxoSmithKline

Recruiting

Niraparib In Recurrent IDH 1/2 Gliomas

Recurrent Glioma | Low-grade Glioma | Glioma, Malignant | IDH2 Gene Mutation | IDH1 Mutation

United States
NRG Oncology
National Cancer Institute (NCI)

Active, not recruiting

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma

Glioma | Oligoastrocytoma | Anaplastic Astrocytoma | Oligodendroglioma | Diffuse Astrocytoma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | 1p/19q Co-deletion

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); BeiGene

Completed

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | IDH1 Mutation | IDH2 Mutation

United States
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Recruiting

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

IDH1-mutant Cholangiocarcinoma

United States, United Kingdom
University of California, San Francisco
BeiGene USA, Inc.; Pacific Pediatric Neuro-Oncology Consortium

Recruiting

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017)

Glioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent WHO Grade III Glioma | WHO Grade III Glioma | IDH2 Gene Mutation | IDH1 Gene Mutation | Low Grade Glioma | Recurrent WHO Grade II Glioma | WHO Grade II Glioma

United States
University of Utah

Terminated

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Primary Myelofibrosis | Anemia | Thrombocytopenia | Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | IDH2 Gene Mutation | IDH1 Gene Mutation | Secondary Myelofibrosis | ASXL1 Gene Mutation | EZH2 Gene Mutation

United States
Juan M Garcia-Gomez
Hospital Universitario 12 de Octubre; Hospital Clínico Universitario de Valencia

Recruiting

BIOhabitats: Biological Validation of Vascular Habitats Within Astrocytoma Grade 4 at Molecular, Cellular, and Histopathological Levels (BIOhabitats)

Glioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Mutant

Spain
Heinrich-Heine University, Duesseldorf
Celgene Corporation; Koordinierungszentrum für Klinische Studien Düsseldorf

Active, not recruiting

IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Chronic Myelomonocytic Leukemia | IDH2 Gene Mutation | IDH2 R172 | IDH2 R140

Germany
Jason J. Luke, MD
Bristol-Myers Squibb; Agios Pharmaceuticals, Inc.

Completed

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors

Glioma | Advanced Solid Tumor | IDH1 Mutation

United States
Memorial Sloan Kettering Cancer Center
Agios Pharmaceuticals, Inc.

Recruiting

AG-120 in People With IDH1 Mutant Chondrosarcoma

Chondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3

United States
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation (AGIR)

Recurrent IDH1/2 Mutated Glioma

France
Servier Bio-Innovation LLC
Institut de Recherches Internationales Servier

Not yet recruiting

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen (CHONQUER)

Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
University Health Network, Toronto
AbbVie; Celgene

Terminated

Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

Acute Myeloid Leukemia | Relapsed Cancer | Refractory Cancer | IDH2 Gene Mutation

Canada
Orbus Therapeutics, Inc.

Recruiting

Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Glioblastoma | Glioblastoma Multiforme | GBM | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

United States
Tocagen Inc.

Terminated

A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

Melanoma | Sarcoma | Lymphoma | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Bladder Cancer | Triple Negative Breast Cancer | IDH1 Mutated Solid Tumors | IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

United States
National Cancer Institute (NCI)

Active, not recruiting

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Astrocytoma, IDH-Mutant, Grade 2 | Astrocytoma, IDH-Mutant, Grade 3

United States
Massachusetts General Hospital
National Cancer Institute (NCI)

Active, not recruiting

Proton Radiation Therapy for Gliomas

Low Grade Glioma | WHO Grade 3 Glioma With IDH1 Mutation | WHO Grade 3 Glioma With 1p/19q Codeletion

United States
National Cancer Institute (NCI)

Suspended

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden

Diffuse Glioma | Secondary Glioblastoma | Glioblastoma, IDH-Wildtype | Astrocytoma, IDH-Mutant, Grade 4

United States, Puerto Rico
University Health Network, Toronto

Recruiting

Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID)

Glioma | Solid Tumor | Cholangiocarcinoma | IDH Mutation

Canada
M.D. Anderson Cancer Center
DNAtrix, Inc.

Recruiting

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Gliosarcoma | Recurrent Anaplastic Astrocytoma | IDH1 wt Allele

United States
M.D. Anderson Cancer Center

Recruiting

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

Glioblastoma | Anaplastic Oligoastrocytoma | Oligoastrocytoma | Oligodendroglioma | Anaplastic Oligodendroglioma | WHO Grade III Glioma | Diffuse Astrocytoma, IDH-Wildtype | WHO Grade II Glioma | Anaplastic Astrocytoma, IDH-Wildtype

United States
Institut de Recherches Internationales Servier

Recruiting

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Myelodysplastic Syndromes | Relapsed or Refractory Acute Myeloid Leukemia (AML) | Untreated AML | Other IDH1-mutated Positive Hematologic Malignancies

United States, France
Shuttle Pharmaceuticals, Inc.

Not yet recruiting

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Glioblastoma, IDH-wildtype

United States
University Hospital Inselspital, Berne
Swiss National Science Foundation

Recruiting

Metabolic Characterization of Space Occupying Lesions of the Brain (FASTMRSI)

Glioma | Brain Tumor | IDH Mutation

Switzerland
Tianjin Medical University General Hospital

Recruiting

Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma

Glioblastoma, IDH-wildtype

China
Peking Union Medical College Hospital

Not yet recruiting

Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma

Glioblastoma, IDH-wildtype

China
Fondazione Policlinico Universitario Agostino Gemelli...
Oslo University Hospital; Istituto Superiore di Sanità; University Medical Center... and other collaborators

Not yet recruiting

Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma (IPerGlioGEM)

Glioblastoma, IDH-wildtype

Italy
Ottawa Hospital Research Institute

Recruiting

THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM) (THERABIOME-GBM)

Glioblastoma, IDH-wildtype

Canada
Hopital Foch
National Cancer Institute, France

Not yet recruiting

Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM)

Glioblastoma, IDH-wildtype

France, Italy
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Recruiting

Study of Niacin in Glioblastoma

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Canada
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Renal Cell Carcinoma | Non Small Cell Lung Cancer | Mesothelioma | Solid Tumors | Triple-Negative Breast Cancer | Fumarate Hydratase (FH)-Deficient Tumors | Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) | Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal... and other conditions

United States
University of Texas Southwestern Medical Center
Bayer

Withdrawn

Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma

Glioma | IDH Mutation
European Institute of Oncology

Active, not recruiting

CDH1 Germline Mutations in Lobular Breast Cancer

Lobular Breast Carcinoma | CDH1 Gene Inactivation

Italy
University of Milano Bicocca

Not yet recruiting

Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma

Malignancies | Glioblastoma, IDH-wildtype | Metformin

Italy
Istituto Oncologico Veneto IRCCS
Bayer S.p.A

Recruiting

Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2)

Glioblastoma, IDH-wildtype | MGMT-Methylated Glioblastoma

Italy
Northwestern University
National Cancer Institute (NCI); Moleculin Biotech, Inc.

Not yet recruiting

WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-Wildtype

United States
Stephen Bagley, MD, MSCE
University of Pennsylvania; Incyte Corporation

Recruiting

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Glioma | Astrocytoma | Oligodendroglioma | IDH Mutation

United States
Vastra Gotaland Region
Karolinska Institutet; Oslo University Hospital; Aarhus University Hospital; Sahlgrenska... and other collaborators

Not yet recruiting

Lomustine in Addition to Standard of Care in Patients With MGMT Methylated Glioblastoma

Glioblastoma, IDH-wildtype | MGMT-Methylated Glioblastoma
Sunnybrook Health Sciences Centre

Recruiting

UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly (UNITED2)

Glioblastoma, IDH-mutant | Glioblastoma Multiforme, Adult

Canada
Oslo University Hospital
Karolinska University Hospital; University Hospital of North Norway; Sahlgrenska... and other collaborators

Recruiting

PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas (PRO-GLIO)

Oligodendroglioma | Oligodendroglioma, Anaplastic | Diffuse Astrocytoma, IDH-Mutant

Norway
Jasper Gerritsen
Massachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaborators

Recruiting

The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201) (SUPRAMAX)

Glioblastoma | Brain Neoplasms | Astrocytoma, Grade III | High-grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Brain Neoplasm, Primary | Brain Neoplasm, Malignant | Astrocytoma, Malignant | Brain Neoplasms, Adult

United States, Germany, Belgium, Switzerland, Netherlands
Hospital San Carlos, Madrid
Asociación de Afectados Por Tumores Cerebrales en España (ASATE)

Recruiting

Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma (GLINERA)

Glioblastoma | Glioblastoma Multiforme | Radiotherapy; Complications | Glioblastoma, IDH-wildtype | Cancer Brain

Spain
Northwestern University
Agenus Inc.; CarThera

Recruiting

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Glioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype

United States
ECOG-ACRIN Cancer Research Group

Not yet recruiting

Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial

Glioblastoma, IDH-Wildtype

Clinical Trials on IDH1 R132G

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations